semaglutide biomarkers alzheimer GLP-1 drugs failed to slow Alzheimer's in two big clinical trials Novo Nordisk Alzheimer's drug trials

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality

Schedule a consultation by calling (703)361-4375 Get a personalized health evaluation Begin your Semaglutide treatment plan with professional support Visit Altmed Medical Center at 8551 Rixlew Lane Suite 140A, Manassas, VA, or call us at (703)361-4357 to learn more about GLP-1 Semaglutide therapy and start your weight loss journey today

Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects

Hyaluronic acid is naturally present in the skin and helps maintain hydration, volume, and elasticity

Starting Semaglutide Semaglutide is usually started at a low dose and increased gradually

It suits those with a BMI of 27 or higher, who have tried but struggled to lose weight, and who have experienced knee pain for more than 12 weeks